IPCALAB IN EQUITY
loading…—
Day range—
52-week range—
Market cap—
P/E · TTM—
As of—
| CUSTOMER | BASIS | EST ₹CR | RANGE | % REV | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| Others | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “7 Other Non-Financial Assets (₹ Crores) Particulars As at March 31, 2025 As at March 31, 2024 Non Current Current Non Current Current (i) Capital advances (Uns…” AR · +1 DOC | ||||||||
| Appointed Date | UNSTATED | — | — | — | CAPEX | FY26 | EST | 75% |
| “Additional disclosure in view of amendments to the Schedule III to the Companies Act, 2013 vide Notification dated 24th March, 2021: (i) Title deeds of Immovab…” AR · +1 DOC | ||||||||
| Maharashtra | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “Manufacturing facilities sold/closed down As part of the Company’s operational strategy and to reduce number of manufacturing units and in order to minimize op…” AR DOC | ||||||||
| Australia | UNSTATED | — | — | — | COGS | FY26 | EST | 75% |
| “Australasia The Company exports APIs to Australia and formulations to Australia and New Zealand in this sub-continent.” AR · +1 DOC | ||||||||
| United States | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “Nearly half of the India’s pharmaceutical exports are directed to highly regulated markets such as Europe and United States.” AR DOC | ||||||||
| Business | UNSTATED | — | — | — | — | FY25 | EST | 75% |
| “Description of property Gross carrying value (` in Crores) Held in name of Whether promoter, director or their relative or employee Period Held Reason for not …” AR · +1 DOC | ||||||||
| Business | UNSTATED | — | — | — | CAPEX | FY26 | EST | 75% |
| “Additional disclosure in view of amendments to the Schedule III to the Companies Act, 2013 vide Notification dated 24th March, 2021: (i) Title deeds of Immovab…” AR · +1 DOC | ||||||||
| Appointed Date | UNSTATED | — | — | — | — | FY25 | EST | 75% |
| “Description of property Gross carrying value (` in Crores) Held in name of Whether promoter, director or their relative or employee Period Held Reason for not …” AR DOC | ||||||||
| BANKINDIABank of India | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “We are informed by the management, that no order that has been passed by Company Law Board or National Company Law Tribunal or Reserve Bank of India or any Cou…” AR · +1 DOC | ||||||||
| RBLBANKRBL Bank Ltd. | CONTRACT | CT 11 | — | — | R&D | FY26 | EST | 70% |
| “Less: Loss Allowances - (13.06) - - Claim receivables - 13.43 - 42.49 Unbilled revenue - 10.32 - 8.10 Forward contract gain receivable - 5.04 - 11.49 Term depo…” AR · +1 DOC | ||||||||
| Securities and Exchange Board of India | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “(Not applicable to the Company during the audit period) (f ) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regu…” AR · +1 DOC | ||||||||
| Mumbai | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “CIN: L24239MH1949PLC007837 Mumbai, 29th May, 2025 By Order of the Board For Ipca Laboratories Ltd. Harish P. Kamath Corporate Counsel & Company Secretary ACS 6…” AR · +1 DOC | ||||||||
| Business | UNSTATED | — | — | — | COGS | FY25 | EST | 70% |
| “VI CSR Details Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes A Turnover (in `) 7431.39 Crores B Net worth (in `) 7979.35 Crores VII …” AR DOC | ||||||||
| FY27 | UNSTATED | — | — | — | — | FY27 | EST | 65% |
| “Overall export business has delivered growth of around 34% for Q1 FY27 to around INR603 crores from INR450 crores in Q1 FY26.” CONCALL DOC | ||||||||
| Central Goods and Service | CONTRACT | — | — | — | — | FY26 | EST | 65% |
| “Updates The Company has enclosed herewith intimation under regulation 30 regarding order received from Central Goods and Service Act,2017” ANN · 26-JUN-25 DOC | ||||||||
| CDSLCentral Depository Services (India) Ltd. | UNSTATED | — | — | — | — | FY26 | EST | 60% |
| “8 Character DP ID followed by 8 Digit Client ID For example if your D P ID is IN300*** and Client ID is 12****** then your user ID is IN300***12****** b) For M…” AR · +1 DOC | ||||||||
| Australia | UNSTATED | — | — | — | — | 2025-11 | EST | 60% |
| “And a lot of places, there are kets like Australia, New and so those bioequivalent studies and all are required, then somewhere trade dress needs to be matched…” CONCALL DOC | ||||||||
| SOURCE | READ | % | LAST READ |
|---|---|---|---|
| ANNOUNCEMENTS | 4/4 | 100% | 07-NOV-26 |
| ANNUAL | 2/2 | 100% | 15-OCT-26 |
| CONCALL | 4/4 | 100% | 15-OCT-26 |
| ORDERS | 4/4 | 100% | 07-NOV-26 |
| RATINGS | 0/1 | 0% | — |
| SCREENER | 1/1 | 100% | 08-NOV-26 |
| SIGNAL | VALUE | AS OF | INPUTS |
|---|---|---|---|
| CUST MOM 1M | +11.1% | 14-NOV-26 | from 15-OCT-26 · Bank of India +18.2% w 0 · Central Depository Services (India) Ltd. +11.9% w 0 · RBL Bank Ltd. +3.1% w 0 |
| DISTRESS SCORE | 0.126 | 12-OCT-26 | roe 0.15 · operatingMargin 0.21 · debtToEquity 0.1 · interestCoverage 20.91 · assetTurnover 0.78 · leverage 1.53 |
| SUPP MOM 1M | +8.5% | 14-NOV-26 | from 15-OCT-26 · JSW Energy Ltd. +8.5% |